ARBs and angiotensin converting enzyme inhibitors (ACEIs) are substantially less expensive and, in combination with beta blockers (BBs), are associated with improved survival (OR = 0.27, p = 0.03) and fewer cancer-related hospitalizations (hospitalization ratio per year survived from ~3.5 to 1, p = 0.006) in patients with CRC [25]. This evidence concerns the gene ACE and colorectal carcinoma.